AtomVie Global Radiopharma

Executive Summary

AtomVie Global Radiopharma is a privately held, commercial-stage company based in Buffalo, New York, specializing in the production and distribution of radiopharmaceuticals for diagnostic imaging and targeted cancer therapy. Founded in 2019, the company has raised $40 million and operates in the rapidly growing radiopharmaceuticals market, which is driven by increasing demand for precision medicine and theranostic approaches. AtomVie's expertise spans the entire supply chain, from manufacturing to logistics, enabling reliable delivery of short-lived radioisotopes to healthcare providers. With a workforce of 200–500 employees, the company has established itself as a key player in the North American radiopharma landscape, serving both hospital and clinic networks. Looking ahead, AtomVie is well-positioned to capitalize on the expanding use of radiopharmaceuticals in oncology. The company's commercial-stage operations and manufacturing capabilities provide a foundation for growth, though specific revenue and product details remain undisclosed. Key drivers include potential expansions of production capacity to meet growing demand, strategic partnerships with larger pharmaceutical firms for drug development and distribution, and possible regulatory milestones for new diagnostic or therapeutic agents. As the radiopharma sector continues to attract investment and regulatory support, AtomVie's focus on reliable supply and targeted therapies may drive sustained momentum.

Upcoming Catalysts (preview)

• Q3 2026Expansion of radiopharmaceutical manufacturing facility70% success
• H2 2026Strategic partnership with a major pharmaceutical company for distribution60% success
• Q1 2027FDA approval of a new diagnostic imaging agent50% success